{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T09:34:14Z","timestamp":1782898454955,"version":"3.54.5"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"publisher","award":["IRG 2015\u2013003"],"award-info":[{"award-number":["IRG 2015\u2013003"]}],"id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.jchromb.2018.06.043","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T21:23:18Z","timestamp":1530048198000},"page":"489-498","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Determination of voriconazole and co-administered drugs in plasma of pediatric cancer patients using UPLC-MS\/MS: A key step towards personalized therapeutics"],"prefix":"10.1016","volume":"1092","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3270-6804","authenticated-orcid":false,"given":"Medhat A.","family":"Al-Ghobashy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah M.","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada M.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali K.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"ElZeiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa T.","family":"Elrakaiby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed M.","family":"Nooh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Abbassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy K.","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2018.06.043_bb0005","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/pbc.24363","article-title":"Aspergillus galactomannan antigen assay and invasive aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients","volume":"60","author":"Choi","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.jchromb.2018.06.043_bb0010","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jchromb.2016.10.035","article-title":"Development and validation of LC-MS\/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: correlation with genetic polymorphism","volume":"1038","author":"Al-Ghobashy","year":"2016","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2018.06.043_bb0015","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/cid\/ciu911","volume":"60","author":"Herbrecht","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/TCRM.S40160","article-title":"Epidemiology and risk factors for invasive candidiasis","volume":"10","author":"Yapar","year":"2014","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0025","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1093\/jac\/dku241","article-title":"Invasive aspergillosis caused by Aspergillus terreus: an emerging opportunistic infection with poor outcome independent of azole therapy","volume":"69","author":"Hachem","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0030","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00277-015-2333-z","article-title":"Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients\u2014an evidence-based approach","volume":"94","author":"Karthaus","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0035","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/FTD.0000000000000425","article-title":"Impact of CYP2C19 genotype and liver function on voriconazole pharmacokinetics in renal transplant recipients","volume":"39","author":"Li","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0040","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3201\/eid2201.150848","article-title":"Azole resistance of Aspergillus fumigatus in immunocompromised patients with invasive aspergillosis","volume":"22","author":"Alanio","year":"2016","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0045","series-title":"Clarke's Analysis of Drugs and Poisons","author":"Moffat","year":"2011"},{"key":"10.1016\/j.jchromb.2018.06.043_bb0050","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bcpt.12530","article-title":"Variability of voriconazole trough levels in haematological patients: influence of comedications with cytochrome P450 (CYP) inhibitors and\/or with CYP inhibitors plus CYP inducers","volume":"118","author":"Cojutti","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0055","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0060","article-title":"Proton pump inhibitors as chemosensitizer: new indication for a well-known medication","volume":"2","author":"Matuszcak","year":"2015","journal-title":"Cancer Cell Microenviron."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0065","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1128\/AAC.00700-12","article-title":"Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections","volume":"56","author":"Boyd","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijantimicag.2016.11.028","article-title":"Dose optimisation of voriconazole with therapeutic drug monitoring in children: a single-centre experience in China","volume":"49","author":"Liu","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jchromb.2018.06.043_bb0075","series-title":"Elevated Voriconazole Level Associated With Hallucinations and Suicidal Ideation: A Case Report, Open Forum Infectious Diseases","first-page":"ofw215","author":"Jansen","year":"2017"},{"key":"10.1016\/j.jchromb.2018.06.043_bb0080","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.00884-15","article-title":"In vitro study of the variable effects of proton pump inhibitors on voriconazole","volume":"59","author":"Niece","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0085","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ijantimicag.2016.11.025","article-title":"Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole","volume":"49","author":"Qi","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jchromb.2018.06.043_bb0090","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1742-6405-11-25","article-title":"Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity","volume":"11","author":"Bouatou","year":"2014","journal-title":"AIDS Res. Ther."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0095","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0100","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1007\/s11096-014-0011-1","article-title":"Pharmacoepidemiological study of drug\u2013drug interactions in onco-hematological pediatric patients","volume":"36","author":"de Palencia Espinosa","year":"2014","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0105","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2710.2007.00812.x","article-title":"Inherited long QT syndrome revealed by antifungals drug\u2013drug interaction","volume":"32","author":"Eiden","year":"2007","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1399-3062.2006.00160.x","article-title":"Torsades de pointes associated with voriconazole use","volume":"9","author":"Philips","year":"2007","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0115","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mmcr.2014.03.001","article-title":"Voriconazole associated torsades de pointes in two adult patients with haematological malignancies","volume":"4","author":"Brown","year":"2014","journal-title":"Med. Mycol. Case Rep."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0120","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jpba.2017.03.009","article-title":"Ultra-fast quantitation of voriconazole in human plasma by coated blade spray mass spectrometry","volume":"144","author":"Tascon","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0125","first-page":"147","article-title":"Determination of voriconazole in human plasma by liquid chromatography\u2013tandem mass spectrometry","volume":"48","author":"Teng","year":"2016","journal-title":"Bulg. Chem. Commun."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0130","first-page":"135","article-title":"Determination of Voriconazole in rat plasma by UPLC-MS\/MS and its pharmacokinetic study","volume":"35","author":"Wang","year":"2016","journal-title":"Lat. Am. J. Pharm."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0135","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpba.2007.03.026","article-title":"Validation of rapid and simple LC\u2013MS\/MS method for determination of voriconazole in rat plasma","volume":"44","author":"Araujo","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0140","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cca.2012.01.008","article-title":"Fast and simple LC\u2013MS\/MS method for quantifying plasma voriconazole","volume":"413","author":"Pauwels","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jchromb.2018.06.043_bb0145","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1271\/bbb.100474","article-title":"Fast and reliable determination of voriconazole in human plasma by LC-APCI-MS\/MS","volume":"74","author":"Xiong","year":"2010","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0150","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1128\/AAC.00404-10","volume":"54","author":"Decosterd","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0155","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12291-015-0507-z","article-title":"Plasma voriconazole estimation by HPLC","volume":"31","author":"Chawla","year":"2016","journal-title":"Indian J. Clin. Biochem."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0160","first-page":"470","article-title":"Determination of voriconazole in human plasma by HPLC and application to a pharmacokinetic study","volume":"33","author":"Fei","year":"2014","journal-title":"Lat. Am. J. Pharm."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0165","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/jcla.21871","article-title":"Determination of voriconazole concentrations in serum by GC-MS","volume":"30","author":"Smith","year":"2016","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0170","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jchromb.2016.10.045","article-title":"A fabric phase sorptive extraction-high performance liquid chromatography-photo diode array detection method for the determination of twelve azole antimicrobial drug residues in human plasma and urine","volume":"1040","author":"Locatelli","year":"2017","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2018.06.043_bb0175","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jpba.2017.07.040","article-title":"A simple high performance liquid chromatography\u2013mass spectrometry method for therapeutic drug monitoring of isavuconazole and four other antifungal drugs in human plasma samples","volume":"145","author":"Fatiguso","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0180","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/bmc.2878","article-title":"Development and validation of a sensitive and high-throughput LC-MS\/MS method for the simultaneous determination of esomeprazole and naproxen in human plasma","volume":"27","author":"Gopinath","year":"2013","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0185","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jpha.2016.01.001","article-title":"Development and validation of a high throughput UPLC\u2013MS\/MS method for simultaneous quantification of esomeprazole, rabeprazole and levosulpiride in human plasma","volume":"6","author":"Chunduri","year":"2016","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0190","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jchromb.2006.10.074","article-title":"Determination of esomeprazole and its two main metabolites in human, rat and dog plasma by liquid chromatography with tandem mass spectrometry","volume":"848","author":"Hultman","year":"2007","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2018.06.043_bb0195","article-title":"Method validation of esomeprazole analysis in human plasma using high performance liquid chromatography-photodiode array","volume":"9","author":"Harahap","year":"2017","journal-title":"J. Young Pharm."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0200","first-page":"552","article-title":"Development and validation of high performance liquid chromatographic method for the determination of esomeprazol in human plasma","author":"TNVSS","year":"2013","journal-title":"Int. J. Res. Pharm. Chem."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0205","doi-asserted-by":"crossref","first-page":"S3135","DOI":"10.1016\/j.arabjc.2013.12.004","article-title":"Solid phase extraction liquid chromatography mass spectrometry method with electrospray ionization for the determination of ondansetron in human plasma: development and validation consideration","volume":"10","author":"Ninama","year":"2013","journal-title":"Arab. J. Chem."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0210","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jpba.2016.03.013","volume":"124","author":"Maher","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jchromb.2008.02.002","article-title":"Quantitative determination of ondansetron in human plasma by enantioselective liquid chromatography-tandem mass spectrometry","volume":"864","author":"Liu","year":"2008","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2018.06.043_bb0220","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jchromb.2006.03.032","article-title":"Development and validation of a rapid 96-well format based liquid\u2013liquid extraction and liquid chromatography\u2013tandem mass spectrometry analysis method for ondansetron in human plasma","volume":"836","author":"Dotsikas","year":"2006","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2018.06.043_bb0225","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6749087","article-title":"Simultaneous determination of dexamethasone, ondansetron, granisetron, tropisetron, and azasetron in infusion samples by HPLC with DAD detection","volume":"2017","author":"Chen","year":"2017","journal-title":"J. Anal. Methods Chem."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0230","unstructured":"F.G.B.m. validation, DOI (September 2013)."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0235","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2018.06.043_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2015.11.068","article-title":"Simultaneous determination of 200 pesticide residues in honey using gas chromatography-tandem mass spectrometry in conjunction with streamlined quantification approach","author":"Shendy","year":"2016","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jchromb.2018.06.043_bb0245","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1128\/AAC.00054-16","article-title":"Drug-drug interaction associated with mold-active triazoles among hospitalized patients","volume":"60","author":"Andes","year":"2016","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023218307025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023218307025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T17:44:05Z","timestamp":1565286245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023218307025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":49,"alternative-id":["S1570023218307025"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2018.06.043","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of voriconazole and co-administered drugs in plasma of pediatric cancer patients using UPLC-MS\/MS: A key step towards personalized therapeutics","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2018.06.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}